Georgia Tomaras
Professor (with tenure), Department of Surgery
Professor, Department of Immunology
Professor, Department of Molecular Genetics and Microbiology
Dr. Tomaras' overall research program is to understand the cellular and humoral immune response to HIV-1 infection and vaccination that are involved in protection from HIV-1. The research in the Tomaras laboratory centers around three main projects involving 1) antiviral CD8 T cell responses in HIV-1 infection and post vaccination, 2) mucosal and systemic antibody responses to infection and vaccination in both non-human primates and humans and 3) the ontogeny of neutralizing antibodies in HIV-1 infection. Her laboratory is also within the Duke Human Vaccine Institute.
Projects
-
Improved Global HIV-1 Incidence Assay
United States
Publications
-
Wilson SM, Woolley G, Hawn C, Hoffman K, Jones A-AD, Chan C, et al. Intersectional climate justice, health equity, and HIV. Lancet HIV. 2024 Apr 3;Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, et al. Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun. 2024 Mar 22;15(1):2575.Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, Omar FL, Kee JJ, et al. Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar;21(3):e1004360.Verma A, Hawes CE, Elizaldi SR, Smith JC, Rajasundaram D, Pedersen GK, et al. Tailoring Tfh profiles enhances antibody persistence to a clade C HIV-1 vaccine in rhesus macaques. Elife. 2024 Feb 22;12.
See more publications at Scholars@Duke